Arcus Biosciences, Inc. (RCUS) News
Filter RCUS News Items
RCUS News Results
|Loading, please wait...|
RCUS News Highlights
- RCUS's 30 day story count now stands at 9.
- Over the past 23 days, the trend for RCUS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about RCUS are PD, LUNG and MARA.
Latest RCUS News From Around the Web
Below are the latest news stories about Arcus Biosciences Inc that investors may wish to consider to help them evaluate RCUS as an investment opportunity.
HAYWARD, Calif., February 24, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 20,450 shares of the Company’s common stock at an exercise price per share of $30.01, which was the closing price on February 23, 2022, and restricted stock units to acquire a total of 10,
Arcus Biosciences press release (RCUS): Q4 GAAP EPS of $3.71 beats by $4.33.Revenue of $354.5M (+3635.5% Y/Y) beats by $305.07M.“Arcus is starting 2022 with a strong cash position…
Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across common cancers, including lung
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HAYWARD, Calif., February 15, 2022--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate at the following upcoming investor conferences:
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $51.00. The company's shares closed last Friday at $29.71. According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 9.2% and a 38.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Corvus Pharmaceuticals, and Neoleukin Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $64.89, which is an 111.4% upside from current levels.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Profits fell far short of expectations and management offered financial forecasts that appeared to disappoint Wall Street.
Livonia, MI, based Investment company White Pine Investment CO (Current Portfolio) buys Amazon.com Inc, BTC iShares Morningstar Large-Cap Growth ETF, AbbVie Inc, sells VanEck Merk Gold Trust, Arcus Biosciences Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, White Pine Investment CO.
Arcus Biosciences (RCUS) granted six new employees options to buy a total of 38,850 common shares at $31.75 apiece and restricted stock units to acquire a total of 925 shares.The…